Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

Condition:   Autosomal-dominant Hyper-IgE Syndrome
Intervention:   Drug: NDV-3A
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 18, 2016
News Type: